19 May 2013
Keywords: merck, serono, initiates, ph, ii, trial, cladribine
Article | 29 January 2007
German-Swiss drugmaker Merck Serono has initiated a Phase II study to evaluate the safety, tolerability and efficacy of two dose ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 January 2007
17 May 2013
© 2013 thepharmaletter.com